Novartis
Last updated: . For recent data, use our API.
Overview
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. The company traces its roots back more than 250 years and has operated as Novartis for 30 years. It has about 77,000 employees and sells products in 118 countries.
Novartis focuses on core therapeutic areas with high unmet patient needs: cardiovascular, renal and metabolic; immunology; neuroscience; and oncology. Its research draws on several technology platforms, including chemistry, biotherapeutics, xRNA, radioligand therapy, and gene and cell therapy. The company describes its strategy as delivering medicines that address major disease burdens, supported by R&D technology and new approaches to patient access.
Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
Private funding before listing
Disclosed funding: $106.5M across 2 rounds. Latest: Post-IPO Debt, 13 May 2026.
| Date | Type | Amount |
|---|---|---|
| 13 May 2026 | Post-IPO Debt | Not disclosed |
Office locations
- Basel, Basel-Stadt, CH
- East Hanover, New Jersey, US
- Usme, Distrito Capital, CO
- Dublin 4, IE
- Prague, CZ
- Bella Vista, PA
- København, Region Hovedstaden, DK
- Tirana, AL022, AL
- Buenos Aires, Autonomous City of Buenos Aires, AR
- Macquarie Park, New South Wales, AU
- Vienna, AT
- Kundl, Tyrol, AT
- Baku, Baku City, AZ
- Amsterdam, North Holland, NL
- Auckland, NZ
- Ikeja, Lagos State, NG
- Skopje, MK
- Oslo, NO
- Muscat, OM
- Karāchi, Sindh, PK
- Panama City, PA
- Lima, PE
- Makati, PH
- Warsaw, MA, PL
- Porto Salvo, PT
- PR
- Dhaka, BD
- Saint Michael, BB
- Minsk, BY
- Brussels, BE
- Sarajevo, Federation of Bosnia and Herzegovina, BA
- Sao Paulo, BR
- Sofia, BG
- Communauté urbaine de Douala, Littoral, CM
- Quebec, CA
- Santiago, Santiago Metropolitan Region, CL
- Beijing, CN
- Shanghai, CN
- Bogota, CO
- San José, CR
- Abidjan, CI
- Zagreb, City of Zagreb, HR
- Willemstad, CW
- Doha, QA
- Bucharest, RO
- Yekaterinburg, RU
- Kazan, RU
- Moscow, RU
- Novosibirsk, RU
- Rostov-on-Don, RU
- Saint Petersburg, RU
- Ad Dammām, SA
- Jeddah, SA
- Riyadh, SA
- Dakar, Dakar Region, SN
- New Belgrade, Central Serbia, RS
- Singapore, SG
- Bratislava, SK010, SK
- Ljubljana, SI
- Kempton Park, ZA
- Seoul, KR
- Barcelona, Catalonia, ES
- Sardón de Duero, ES
- Colombo, Western Province, LK
- Montevideo, UY
- Tashkent, UZ
- Caracas, Federal District, VE
- Ho Chi Minh City, VN
- Lusaka, Lusaka Province, ZM
Similar companies
- PfizerPharmaceutical Manufacturing · New York
- SanofiPharmaceutical Manufacturing · Paris, France
- RocheBiotechnology Research
- AstraZenecaPharmaceutical Manufacturing · Cambridge, Cambridgeshire
- Eli Lilly and CompanyPharmaceutical Manufacturing · Indianapolis, Indiana
- GSKPharmaceutical Manufacturing · London, England
- Johnson & JohnsonHospitals and Health Care · New Brunswick, NJ
- Novo NordiskPharmaceutical Manufacturing
- BayerChemical Manufacturing · Leverkusen, North Rhine-Westphalia
- AbbViePharmaceutical Manufacturing · North Chicago, Illinois
Latest videos from Novartis on YouTube
Redefining CML care at Novartis
Community Health Takes a Village | screening in the Barber’s Chair
Innovating in manufacturing at Novartis
Next Generation Scientist 2026
Recent posts from the Novartis blog
- From color dyes to RNA medicines.
For more than 200 years, Schweizerhalle has adapted to changing industries, technologies and scientific breakthroughs. Today, behind the walls of a historic manufacturing site, teams are producing some of the most advanced medicines yet.
- Cross one New York City street, and life expectancy can drop by up to 11 years.
Same city. Same skyline.